checkAd
    Centessa Pharmaceuticals Aktie
    9,9000
     
    EUR
    -2,94 %
    -0,3000 EUR
    Letzter Kurs 18.04.24 Tradegate
    9,5000
     
    EUR
    318 STK
    Geldkurs 08:58:26
    10,200
     
    EUR
    293 STK
    Briefkurs 08:58:26
    ISIN: US1523091007 · WKN: A3CQ72 · SYM: 260 · Großbritannien

    Neueste Nachrichten

    Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
    28.03.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
    22.02.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
    09.02.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
    22.01.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
    13.11.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
    02.11.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
    31.10.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
    30.10.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
    25.10.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
    03.10.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
    31.08.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
    23.08.23 · globenewswire · Centessa Pharmaceuticals